Table 1.

Sociodemographic, clinical, and serological characteristics of individual patients diagnosed with anti‐TNF‐induced lupus

Age	Gender	IBD	Anti‐TNF	Duration of therapy (months)	Immunomodulator	Clinical Symptoms	ANA (baseline) (<7 IU/mL)	ANA (at diagnosis) (<7 IU/mL)	dsDNA (<7 IU/mL)	Anti‐histone	Anti‐Smith	Anti‐CCP	RF (<14k U/L)
48	M	CD	Infliximab	21	Nil	Polyarthritis	0	30	38	Pos	Neg	NA	NA
69	F	CD	Infliximab	6	Nil	Polyarthritis	5	25	35	Neg	Neg	1	<10
34	F	CD	Infliximab	9	MMF	Rash	NA	30	NA	Neg	Neg	NA	NA
57	F	CD	Infliximab	10	Nil	Polyarthritis,	6	15	10	Neg	Neg	NA	<10
53	F	UC	Infliximab	3	Nil	Polyarthritis, Rash	2	10	0	Pos	Neg	1	11
51	F	CD	Infliximab	30	AZA	Polyarthritis	NA	30	NA	Neg	Neg	NA	NA
37	F	CD	Infliximab	9	AZA	Polyarthritis	2	30	NA	NA	NA	NA	NA
53	F	CD	Infliximab	10	MTX	Polyarthritis	0	30	22	Neg	Neg	NA	NA
39	M	CD	Infliximab	44	Nil	Rash	0	30	35	Neg	Neg	1	<10
62	F	CD	Infliximab	30	6MP	Polyarthritis,	7	30	6	Neg	Neg	NA	NA
36	M	UC	Infliximab	18	Nil	Rash	NA	25	6	Neg	Neg	NA	NA
49	M	CD	Infliximab	7	Nil	Polyarthritis	2	30	5	NA	NA	NA	NA
45	F	UC	Infliximab	33	Nil	Rash	7	30	7	Neg	Neg	NA	NA
21	M	CD	Infliximab	12	Nil	Polyarthritis	7	30	11	Neg	Neg	NA	<10
42	F	CD	Infliximab	21	Nil	Polyarthritis	5	30	39	Neg	Neg	5	<10
77	F	CD	Infliximab	3	Nil	Polyarthritis	NA	7	53	NA	NA	NA	<10
51	F	CD	Infliximab	28	Nil	Polyarthritis	2	30	6	Neg	Neg	2	<10
41	F	CD	Adalimumab	62	Nil	Polyarthritis Polyarthritis	0	30	52	Neg	Neg	NA	NA

Age–age at diagnosis of ATIL, Immunomodulator—concurrent at time of diagnosis.

AZA, Azathioprine; MMF, mycophenolate mofetil; MTX, methotrexate; 6MP, 6 mercaptopurine.